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Abstract (< 100 words, per instructions) 
 
Recent research has advanced our understanding of the molecular and cellular mechanisms of 
cerebral edema (“brain swelling”). This has led, in turn, to the development of novel anti-edema 
therapeutics. Current evidence supports aberrant neuro-glial ion transport as a central 
mechanism that underlies pathological fluid accumulation after central nervous system (CNS) 
injury. Novel agents in the clinical development pipeline are showing promise in altering the 
natural history and treatment of cerebral edema. In this review, we discuss these agents that are 
under active investigation, their mechanism, and clinical application in clinical trials.   
 




Cerebral edema, the pathological accumulation of fluid in the brain parenchyma, is caused by 
multiple traumatic and pathological insults, including traumatic brain injury (TBI), stroke (both 
hemorrhagic and ischemic), infection, primary and metastatic tumors, and inflammatory disease. 
Even some systemic diseases, including acute liver failure and diabetic ketoacidosis, can lead to 
brain swelling. Regardless of the inciting event, a common consequence of cerebral edema is the 
elevation of intracranial pressure (ICP). Swelling brain tissue and increasing ICPs result in 
compromised cerebral blood flow, ischemia, cell death, and neurological deficits.1 Although the 
severity, location, and extent of swelling determine the specific downstream consequences, the 
side effects are often severe, frequently affecting patient’s functional outcome and increasing 
mortality to upwards of 80%.1 
 
2. Management of Cerebral Edema 
 
The Monro-Kellie doctrine first described by Dr. Alexander Monro and Dr. George Kellie more 
than two centuries ago, is a well-accepted principle in neurological disease. This principle states 
that the sum of the volumes of intracerebral blood, cerebrospinal fluid, and brain tissue, consisting 
of interstitial and intracellular fluid, is constant given the constraints of a rigid skull.2 An increase 
in one must cause a reciprocal decrease in the others. Therefore, current management of cerebral 
edema focuses on temporizing tissue swelling and decreasing ICPs in effort to prevent brain 
herniation and ischemia due to effects of high pressures and loss of cerebral blood flow.  
 
Osmotherapy, a common first line management, consists of intravenous administration of 
hypertonic solution (i.e. mannitol or hypertonic saline). Following Starling’s principle, creating an 
osmotic gradient across blood vessels causes water to move from the intra- and extra-cellular 
compartments of the brain into the vasculature, decreasing parenchymal fluid volume. This 
movement of water along an imposed ionic gradient serves to decrease intracranial volume, and 
as a result, pressures. In addition to osmotherapy, decadron, a glucocorticoid, is commonly used, 
especially in the setting of tumor-induced edema.3 Other less commonly used medications for 
edema include loop diuretics (i.e. furosemide), anti-inflammatory agents, and barbiturates.  
 
Although often first line, medical management is largely temporizing and exposes patients to 
significant side effects during administration, as well as rebound swelling when therapy is 
discontinued. Surgical management with decompressive craniectomy is often required if medical 
therapy fails, or as initial management if the edema is too extensive and urgent intervention is 
needed. Interestingly, these strategies to reduce cerebral swelling and increasing ICP have been 
used for over a century. 
 
3. Pathophysiology of Cerebral Edema 
 
Cerebral edema is traditionally classified as cytotoxic or vasogenic, based on location of fluid 
accumulation. Vasogenic edema causes increased extracellular fluid due to blood-brain barrier 
(BBB) breakdown, while cytotoxic edema occurs when water accumulates in the intracellular 
space, resulting in cell swelling. Ionic cerebral edema, more recently defined as a subset of 
cytotoxic edema, consists of vessel leakage into the extracellular space through an intact BBB. 
 
While historical classifications remain useful, current research is advancing our understanding of 
the mechanisms underlying cerebral edema. Water balance intracranially is based on intra- and 
extra-cellular and vascular ionic gradients, which are primarily dictated by cellular transporters 
and channels. Therefore, current theories ascribe the pathophysiology of cerebral edema to 
alterations in intracranial ion transport, and new pharmacological targets are being investigated.  
 
4. Antiedema Drugs in Development 
 
As our understanding of the pathophysiology of this disease grows, pharmacological treatments 
are being developed to target specific molecular mechanisms underlying cerebral edema. New 
candidates are showing promise attenuating tissue swelling and improving functional outcomes 
in in vivo models and clinical trials. Table 1 illustrates these novel therapeutic agents currently 
under development.  
 
4.1 Cation-Chloride Cotransporter (CCC) Regulation 
 
Intracranial ionic homeostasis is, in part, maintained by cation-Cl- cotransporters (CCC), 
specifically NKCC1 and the KCCs. Through phosphorylation, SPS1-related proline/alanine-rich 
(SPAK) kinase is a master regulator of both, stimulating NKCC1 and inhibiting KCC. As 
electroneutral cotransporters, NKCC1 imports and KCC1-4 export Cl- by utilizing the 
transmembrane gradients of Na+ and/or K+. Their coordinated regulation is required for 
appropriate cellular response and volume changes and prevents pathological cell volume 
changes in response to alterations in osmotic gradients. SPAK, in combination with OSR1 
(oxidative stress-responsive kinase 1), ensures control over cellular Cl- concentrations, and as a 
result, water movement and cell volume. In experimental models, enhanced SPAK activity has 
been found in ischemia-induced cerebral edema.  
 
A newly developed selective SPAK inhibitor, ZT-1a (5-chloro-N-(5-chloro-4-((4-
chlorophenyl)(cyano)methyl)-2-methylphenyl)-2-hydroxybenzamide), is a modulator of both 
NKCC1 and KCC, inhibiting and activating these cotransporters, respectively. SPAK inhibition 
with ZT-1a stimulates Cl- -dependent K+ export, and improved regulation of cellular volume after 
insult. In animal models, ZT-1a reduces ischemia-induced CCC phosphorylation, and results in 
decreased cerebral edema and improved functional outcomes.4 Given the specificity of this agent 
and the promising in vivo results, ZT-1a has significant therapeutic potential for cerebral edema.  
 
4.2 SUR1-TRMP4 Inhibition  
 
The sulfonylurea receptor 1 (Sur1) is an ion channel important in cerebral ion homeostasis. Sur1 
association with transient receptor potential melastatin 4 (Trpm4) creates SUR1-TRPM4, a non-
selective cation channel upregulated in neurons, astrocytes, microglia, oligodendrocytes, and 
microvascular endothelial cells after cerebral ischemia. SUR1-TRPM4 generates a complex with 
AQP4, increasing the influx of cations and water into cells, particularly astrocytes. In addition, 
SUR1 expression contributes to vascular damage that may play a role in vasogenic edema.3 
Glyburide, a second-generation sulfonylurea developed for type 2 diabetes mellitus, targets 
SUR1-TRPM4 channels and inhibits its upregulation after central nervous system (CNS) injury. 
In vivo work shows glyburide-mediated inhibition after ischemic injury reduces brain swelling and 
death.5 With the conclusion of phase 2 clinical trials, evidence supports administration of 
intravenous glyburide; the greatest benefit was observed in stroke patients with large hemispheric 
infarcts, with a reduction in parenchymal swelling and improved functional outcomes and mortality 
(ClinicalTrials.gov Identifiers: NCT01268683; NCT01794182). Given this success, a phase 3 
clinical trial is currently underway (ClinicalTrials.gov Identifiers: NCT02864953). 
 
4.3 Vascular Endothelial Growth Factor (VEGF) Inhibition 
 
Intracranial malignancies, both primary and metastatic, cause significant peri-lesional edema. 
While the development of tumor-mediated edema is more chronic, it can be difficult to manage 
and often causes significant morbidity and mortality. Vascular endothelial growth factor (VEGF), 
a glycoprotein upregulated in intracranial malignancies, contributes to tumor angiogenesis and 
formation of interendothelial gaps, fragmentations, and fenestrations in the brain endothelium. 
Bevacizumab, a monoclonal immunoglobulin G humanized antibody against VEGF-A, and 
Cerdiranib, a VEGFR tyrosine kinase antagonist, have emerged as promising anti-angiogenic and 
anti-edema therapies.6,7 Although VEGF inhibition by these drugs does not improve overall patient 
survival, animal studies and clinical trials demonstrate normalization of tumor vasculature, 
reduction in the severity of peritumoral edema, and improvement of progression-free survival in 
both animal studies and clinical trials (ClinicalTrials.gov NCT00943826; NCT00305656).  
 
4.4 Arginine Vasopressin (AVP) Receptor Inhibition  
 
Arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), a peptide produced in 
the posterior pituitary, has been indicated in intracerebral volume regulation. AVP exerts 
homeostatic effects via signaling through G protein-coupled receptors expressed on vasculature 
(V1A), the anterior pituitary gland (V1B/V3), and components of the nephron tubule (V2), allowing 
control of body fluid volume. Present in non-pathological CSF, AVP demonstrates an ability to 
increase brain water content,1 and plasma concentrations have been found to be significantly 
increased in stroke patients.8 Furthermore, hyponatremia secondary to the syndrome of 
inappropriate antidiuretic hormone secretion (SIADH) is present in a significant number of TBI 
and SAH patients and indirectly causes worsening brain edema.  
 
Vaptans, small-molecule vasopressin receptor inhibitors, are showing modest effect on controlling 
cerebral edema. Administration of the AVP A1A/A2 receptor inhibitor, conivaptan, demonstrated 
reduction of brain edema in a rodent model, and is now being investigated in an ongoing phase 
1 clinical trial (ClinicalTrials.gov Identifier: NCT03000283). However, while the effects of 
conivaptan on water retention in the kidney have been well characterized, little is known regarding 
the pharmaceutical’s mechanism of action in the brain, warranting further molecular research.  
 
4.5 Inflammatory Cascade Inhibition  
 
Proinflammatory cascades induced by CNS injury often contribute to widespread cerebral edema 
in patients. Cyclooxygenase (COX) enzymes convert arachidonic acid into proinflammatory 
mediators, which play a key pathological role in amplifying injuries, especially in the setting of 
intracerebral hemorrhage (ICH). In rodent models of ICH, COX2 is upregulated in endothelium 
and leukocytes, exacerbating the progression of neuronal cell death, infarct volume, and brain 
edema.1,9 In a retrospective study, ICH patients treated with celecoxib, a non-steroidal inhibitor of 
COX2, demonstrated attenuated hematoma expansion and decreased edema.1 A  2009 pilot 
clinical trial of 44 patients demonstrated similar findings, showing reduced hematoma expansion 
and perihematomal edema in patients treated with celecoxib versus standard management 
(ClinicalTrials.gov Identifier: NCT00526214). Celecoxib treatment following cerebral hemorrhage 
failed to show sustained improvements in functional outcomes, however, further work is being 
done and more specific COX inhibitors are being developed and investigated.10 
 
Signaling through sphingosine-1-phosphate (S1P) and its receptors S1P1-5 stimulates 
propagation of inflammatory responses. Expressed by all cell types in the CNS, S1P receptors 
are upregulated in neuroinflammatory conditions such as stroke. Each receptor type 
demonstrates a unique function determined by its location of expression. S1P1, S1P2, and S1P3, 
expressed on neuro-endothelial cells, regulate vascular and BBB permeability. Given the 
prominent role S1P2 plays in disrupting intercellular adherens junctions and increasing vascular 
permeability, it is of particular interest as a potential therapeutic target in brain edema. Fingolimod, 
a S1P receptor modulator, originally approved to treat multiple sclerosis, is being repurposed for 
treatment of brain edema, with promising preliminary and clinical data. In rodent models of ICH, 
fingolimod mitigated the onset and progression of cerebral edema.11 In a phase 2 clinical trial of 
patients with either ischemic or hemorrhagic stroke, fingolimod reduced perihematomal edema 
and lesional growth, and improved neurological outcomes (ClinicalTrials.gov Identifier: 
NCT02002390). Given the multiple roles of S1P, however, the mechanism by which fingolimod 
exerts its effect remains elusive, necessitating further research. Development of a specific S1P2 
inhibitor may allow direct inhibition of vasogenic edema, mitigating off-target effects. 
 
4.6 Corticotrophin-Releasing Factor Therapy 
 
Although corticosteroid therapy has proven effective for management of cerebral edema, the 
significant systemic side effect profile has prompted development of “steroid-sparing” therapies. 
Of these, human corticotrophin-releasing factor (hCRF) has as shown promise clinically. 
Alternatively named Xerecept, this synthetic, modified hypothalamic peptide demonstrates 
protective effects on brain endothelium and a lower incidence of the severe side effects 
associated with corticosteroid treatment when given systemically. Administration of Xerecept in a 
RG2 cell-derived glioma rodent model significantly reduces vasogenic brain edema12 and a 
completed phase I clinical trial demonstrated improved neurological outcomes and reduced 
peritumoral edema in 10 of 17 primary brain tumor patients.13 A follow up phase 3 clinical trial of 
200 brain tumor patients showed that Xerecept was effective in reducing steroid requirements 





Cerebral edema is a significant contributor to the morbidity and mortality of many central nervous 
system pathologies, especially with acute injuries and disease. Current treatment options are 
limited, and standard of care management include temporizing intracranial pressures with the 
administration of hypertonic solutions, corticosteroids, and in the most severe cases, craniectomy. 
However, as our understanding of the molecular drivers of cerebral edema improves, several new 
therapeutic agents are being developed and tested in animal models and clinical trials with 
promising results. With new and specific pharmacological targets to effectively treat, and even 
prevent, brain swelling, patients may be spared the significant consequences and brain damage 
associated with elevated ICPs and cerebral ischemia.  
 
6. Expert Opinion  
 
As an underlying theme in most neurologic and neurosurgical diseases, cerebral edema 
represents a common secondary pathology leading to increased mortality and neurological 
deficits in patients. Clinical management of edema largely centers on temporizing strategies to 
minimize consequences of acute fluid accumulation, specifically mass effect and elevated ICPs. 
Corticosteroids are used for longer term management; however, their side effect profile often 
limits their utility and chronic administration.  
 
Fortunately, our understanding of the molecular and cellular mechanisms underlying the 
pathophysiology of cerebral edema is growing significantly, allowing the development of targeted 
antiedema agents. The most promising candidates are those targeting the specific molecular 
mechanisms controlling the compensatory post-injury response of ion channels and transporters 
leading to the pathological alteration of osmotic gradients. Although further clinical studies are 
needed, repurposing of drugs such as glyburide to inhibit the aberrant upregulation of ion 
channels like SUR1-TRPM4, and newly developed agents such as ZT-1a which re-establish 
physiological regulation of ion channels like NKCC1/KCC, appear to restore ion gradient 
homeostasis to prevent and reverse fluid accumulation in the brain parenchyma.  
 
Although cerebral edema across all CNS pathologies has a likely common underlying 
pathophysiology, it is important to consider the unique characteristics of these lesion separately. 
TBI, an acute and global CNS injury, likely involves different molecular drivers than peritumoral 
edema or perilesional edema in hemorrhagic or ischemic stroke territories. Similarly, timing of 
drug administration is also a consideration. Injuries such as TBI and ICH stimulate acute 
production of pro-edema environment, such as the upregulation of SUR1-TRPM4 channels and  
enhancement of SPAK activity peri-lesionally. However, in chronic and evolving oncological 
lesions, upregulation of VEGF pathway and inflammatory cascades through both aberrant CNS 
signaling, as well as pathological signaling from the tumor itself, offer alternative pathways for 
drug targets. Repurposing current drugs will be beneficial in shortening the translational timeline 
between in vivo research and clinical application, and agents such as COX2 inhibitors and VEGF 
inhibitor bevacizumab offer critical avenues for expansion of antiedema agents available clinically.  
 
In vivo and clinical trials are gaining momentum and, although there remain hurdles to overcome 
in developing effective and novel therapeutics for cerebral edema, promising targets are being 
identified, driving new pharmaceutical development. As we answer important questions regarding 
the molecular drivers of cerebral edema and treatment strategies, clinical management of cerebral 

















Preclinical Findings Clinical Trials 
Clinical Trial Patient 
Population  
Clinical Trial Results 
ZT-1a SPAK 
Zhang et al. 
20204 
ZT-1a reduced NKCC1 and 
KCC3 phosphorylation, 
mitigating cerebral edema 
and improving functional 
outcomes in a rat model of 
stroke 
N/A N/A N/A 
Glyburide SUR1-TRPM4 
Simard et al. 
20065 
Glyburide attenuated brain 
water volume and decreased 
7-day mortality from 65% to 
24% in a rat model of middle 
cerebral artery occlusion  
NCT01268683; 
Phase 2a; 
Completed in 2013 
10 patients with a 82-
210 mL acute MCA or 
MCA/ACA ischemic 
stroke 
Improved clinical outcomes and 




Completed in 2016 
83 patients with a 82-
300 mL acute MCA 
ischemic stroke 
Attenuated NIH stroke scale scores 
and reduced 30-day mortality rates, 
however, the primary and 
secondary outcome goals were not 
met 
NCT02864953; 
Phase 3; Ongoing 
Aims to recruit 680 
patients with 80-300 mL 




Folkins et al. 
20076 
Bevacizumab reduced BBB 
permeability and normalized 




No identifier; Phase 
2; Completed in 
2007 
32 patients with 
progressive or recurrent 
grade III/IV gliomas who 
were treated with 
radiation and not 
surgical intervention  
Reduced tumor size and edema 




Completed in 2015 
921 patients with stable 
or decreasing 
glucocorticoid use and 
a newly diagnosed, 
untreated glioblastoma 
Improved length of progression-free 
survival and maintenance of 
baseline performance, but failed to 
improve overall survival  
Cerdiranib  VEGFR 
Kamoun et al. 
200914 
Cerdiranib reduced tumor 
vasculature permeability and 




Completed in 2012 
31 patients with a 
confirmed diagnosis of 
glioblastoma 
More typical vascular development 
around the tumor and mitigated 
development of cerebral edema  
Celecoxib COX2 Chu et al. 20049 
Celecoxib treatment in rats 
with induced cerebral 
hemorrhage reduced 
edema, inflammation, and 





Completed in 2009 
44 patients with 
diagnosed intracerebral 
hemorrhage not caused 
by trauma, aneurysmal 
bleeding, or 
anticoagulation 
Mitigated hematoma and 





Wei et al. 201111 
Fingolimod reduced infarct 
volume, neuronal cell death, 
edema, and neurological 
dysfunction in a mouse 




Completed in 2014 
22 patients with 
ischemic stroke or 
intracerebral 




Reduced edema and improved 
neurological outcomes in 
hemorrhage patients and reduced 
lesional expansion and improved 
neurological functioning in stroke 
patients 
Conivaptan  AVP A1A/A2 Can et al. 201915 
Conivaptan was shown to be 
a more potent diuretic than 
mannitol in a rat model of 
ischemic brain injury 
NCT03000283; 
Pilot Trial; Ongoing 
Goal of 7 patients with 
an intracerebral 
hemorrhage of >20 mL 
not due to thrombolysis, 




Tjuvajev et al. 
199612 
Xerecept directly acted on 
tumor microvasculature, 
reducing permeability and 
vasogenic edema in rats with 
RG2 cell-derived gliomas 
No identifier; Phase 
1; Completed in 
1998 
17 patients with primary 
brain tumors and 
radiographic evidence 
of edema 
10 of 17 patients in the clinical trial 




Completed in 2008 
200 patients with a 
brain tumor and 
complications from prior 
steroid use  
Reduced steroid requirements and 
steroid-associated side effects such 





Table 1: Summary of novel therapeutics with promising preclinical and clinical findings in brain edema  
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